Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Allison Elizabeth Jack · UNIVERSITY OF VIRGINIA · 2024 · $2,446,210 — Project Summary Many people with autism spectrum disorder (ASD) are late- or never diagnosed (LDx). Initial data links female sex to LDx. Gender diversity is also overrepresented in ASD and associated with LDx. Autistic people assigned female at birth (ASDaF) and those who are gender diverse (ASDgd)…
William Heerman · VANDERBILT UNIVERSITY MEDICAL CENTER · 2024 · $634,252 — PROJECT SUMMARY Despite the recognition of health disparities in obesity, behavioral interventions among low-income and minority populations have consistently met with limited success. This is partially explained by social determinants of health. Constantly changing barriers at the household and com…
KENNETH Stephen KOSIK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · 2024 · $619,969 — The complex interaction between Alzheimer drivers and aging Project Summary/Abstract (30 lines of text) The greatest risk for Alzheimer’s disease is age. This extremely tight correlation with age has no explanation. However, most of what know about Alzheimer’s comes from early onset cases. We will u…
Deborah Allison Levine · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $745,455 — PROJECT SUMMARY/ABSTRACT Alzheimer’s disease and Alzheimer’s disease-related dementia (AD/ADRD) incidence is high in older adults with stroke. There is a fundamental gap in understanding how vascular risk factors (VRFs) influence risk of post-stroke AD/ADRD. Poor understanding of the biological fact…
Erin H. Norris · ROCKEFELLER UNIVERSITY · 2024 · $412,290 — PROJECT SUMMARY Alzheimer's disease (AD) is a complex neurodegenerative disorder with multiple pathologies, such as proteinaceous brain inclusions and neuroinflammation. The vascular system is also recognized as a factor in AD, yet there are few models to study the mechanism. We and others have foun…
WEN-CHENG XIONG · CASE WESTERN RESERVE UNIVERSITY · 2024 · $643,654 — Alzheimer's disease (AD) is the most common form of dementia, affecting ~10% of the population over 65 years of age. AD is a systemic disorder that affects the brain and peripheral tissues. Patients with AD suffer from declined memory, cognitive deficits, and changes in personality. In addition, AD …
Daniela Annenelie Bota · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $399,338 — PROJECT SUMMARY Glioblastoma (GBM) is the most aggressive primary brain tumor with a two years survival rate of less than 50% following surgical resection, radiation, and chemotherapy. Recurrence is nearly universal after the first-line treatment, and there is currently no therapy proven to prolong …
Wayne M. Yokoyama · WASHINGTON UNIVERSITY · 2024 · $2,757,052 — Enter the text here that is the new abstract information for your application. The Washington University Medical Scientist Training Program at Washington University in St. Louis was established in 1969, and has been continuously funded by the NIH since 1970. It has trained 658 MD-PhDs, more than an…
Sumant Puri · TEMPLE UNIV OF THE COMMONWEALTH · 2024 · $368,909 — Candida albicans exists as a commensal yeast in healthy people while it can cause mucosal and systemic fungal infections including oropharyngeal candidiasis (OPC) in immunocompromised individuals and diabetics. C. albicans has the ability to sense environmental iron as a signal with the help of its …
E. Antonio Chiocca · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $2,680,832 — Abstract Glioblastoma (GBM) remains a formidable cancer to treat with only anecdotal examples of long-term survivors. Recently, immunotherapy has seen multiple successes against various types of cancer, but several recent clinical trials of this modality in GBM have not been successful. It is eviden…
Pew-Thian Yap · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $428,568 — Computational Diffusion MRI for Studying Early Human Brain Development Abstract In the first years of life, the human brain develops dynamically in both structure and function. Many neurodevel- opmental disorders are associated with aberrations from normative growth during this critical period of ear…
ANTHONY P HEANEY · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $339,008 — Abstract Cushing Disease (CD) is a life-threatening “orphan disease” caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma driving excess adrenal cortisol production. There is a large unmet medical need for CD treatment. However, translational research has been greatly hampered…
JOHN M. SULLIVAN · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2024 · $540,069 — Many mutations in the human rod opsin (hRHO) and peripherin genes cause autosomal dominant retinitis pigmentosa (adRP) and macular degenerations. The folded mRNAs are targets for mutation-independent hammerhead ribozyme (hhRz) gene therapy. Our long-range goal is to translate effective hhRz therapeu…
Derek J Doss · VANDERBILT UNIVERSITY · 2024 · $27,218 — PROJECT SUMMARY/ABSTRACT Epilepsy is a debilitating neurological disorder that affects 1% of the population worldwide and temporal lobe epilepsy (TLE) is the most common form. Seizure onset in TLE is typically localized to the mesial temporal lobe, however, patients can suffer from distant effects s…
Gang Lin · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $735,318 — Project Summary/Abstract In 2020, with over 250 million debilitating cases and over half a million deaths, mostly in young children, malaria is a persistent global health crisis. The malaria-causing parasite Plasmodium falciparum (Pf) has developed resistance to most antimalarial drug deployed, incl…
ROBERT G. HOLLOWAY · UNIVERSITY OF ROCHESTER · 2024 · $410,795 — The University of Rochester Medical Center and its neuroscience investigators have provided over four decades of leadership and meaningful contributions to experimental therapeutics for neurological disease. Since the inception of the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT…
Andrew Francis Laine · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $457,803 — Project Summary / Abstract: Chronic obstructive pulmonary disease (COPD) defined by irreversible airflow limitation, is the 3rd leading cause of death globally and 4th in the United States. Smoking tobacco is a major extrinsic COPD risk factor, but despite six decades of declining smoking rates in m…
Junfang Wu · UNIVERSITY OF MARYLAND BALTIMORE · 2024 · $227,884 — Project Summary Despite considerable research over the past 30 years, there is still no established effective treatment to improve recovery following spinal cord injury (SCI). In part, this reflects incomplete understanding of the complex secondary pathobiological mechanisms involved. The aim of our…
JOHN T LIS · CORNELL UNIVERSITY · 2024 · $680,349 — PROJECT SUMMARY/ABSTRACT Human genome is peppered with an estimated one million enhancers that can regulate their specific target gene(s) from a distance up to megabases away, and in an orientation-independent manner. The broad goal of this project is to define the fundamental architecture and funct…
MICHAEL M. SHEN · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $406,495 — Project Summary The clinical use of anti-androgens such as abiraterone and enzalutamide has greatly improved prostate cancer treatment, but patients treated with these drugs still relapse with more aggressive forms of the disease, collectively termed as castration-resistant prostate cancer (CRPC). …